Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura

Pediatric Blood and Cancer

Volumn 55, Issue 3, 2010, Pages 508-511

  Ahmed, Ibrahim ^a,b   Rajpurkar, Madhvi ^a   Thomas, Ronald ^c   Chitlur, Meera ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Hematology; Immune cytopenias; Immune thrombocytopenia; ITP; Platelet disorders; Thrombocytopenia

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BLOOD CELL COUNT; CHILD; ETHNICITY; FEMALE; GENDER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLOOD; CHRONIC DISEASE; INFANT; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

BIOLOGICAL MARKER;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; HUMANS; INFANT; LYMPHOCYTE COUNT; MALE; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 77955480473     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22570     Document Type: Article

References (26)

1. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 2006;133:364-374.
2. Kalpatthi R, Bussel JB. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura. Curr Opin Pediatr 2008;20:8-16.
3. Zeller B, Helgestad J, Hellebostad M, et al. Immune thrombocytopenic purpura in childhood in Norway:Aprospective, population-based registration. Pediatr Hematol Oncol 2000;17:551-558.
4. Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999;105:871-875.
5. Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: Epidemiology and predictors of chronic disease. Acta Paediatr 2005;94:178-184. (Pubitemid 40343692)
6. Reid MM. Chronic idiopathic thrombocytopenic purpura: Incidence, treatment, and outcome. Arch Dis Child 1995;72:125-128.
7. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
8. Glanz J, France E, Xu S, et al. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 2008;121:e506-e512.
9. Watts RG. Idiopathic thrombocytopenic purpura: A 10-year natural history study at the childrens hospital of alabama. Clin Pediatr (Phila) 2004;43:691-702.
10. Nathan DG, Oski FA. Nathan and Oski's hematology of infancy and childhood, Vol.2. Philadelphia, PA: Saunders; 2003. xiv, 1864, xli p.
11. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596.
12. Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 2007;14:515-519.
13. Kuhne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003;143:605-608. (Pubitemid 37452786)
14. Tarantino M. Recent advances in the treatment of childhood immune thrombocytopenic purpura. Semin Hematol 2006;43:S11-S17; discussionS18-S19.
15. Hedman A, Henter JI, Hedlund I, et al. Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden. Acta Paediatr 1997;86:226-227.
16. Culic S, Labar B, Marusic A, et al. Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer 2006;47:671-674.
17. Garcia-Suarez J, Prieto A, Reyes E, et al. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3-natural killer cells subset. Blood 1993;82:1538-1545.
18. Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 2008;3-8.
19. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.
20. Stasi R, EvangelistaML,Stipa E, et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008;99:4-13.
21. Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 2008;112:1325-1328.
22. Beck CE, Nathan PC, Parkin PC, et al. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: A systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005;147:521-527.
23. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
24. Donato H, Picon A, Rapetti MC, et al. Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 2006;47:737-739.
25. Imbach P, Kuhne T, Muller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer 2006;46:351-356.
26. Gernsheimer T. Chronic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis. Oncologist 2009;14:12-21.